ArticleAmino acids2012
Taurine deficiency damages retinal neurones: cone photoreceptors and retinal ganglion cells.
Article in Amino acids, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.
- Pooled it
- Reporter-guided photoreceptor differentiation in 2D culture using PGP1-hIPSCs: A comparable alternative to 3D organoid systems?Molecular vision · 2026Article
- Association of Single Nucleotide Polymorphisms in Cysteamine Dioxygenase Gene with Taurine Content in Oyster Crassostrea gigas.Marine biotechnology (New York, N.Y.) · 2025Article
- A narrative review and new insights into the protective effects of taurine against drug side effects.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- The potential role of amino acids in myopia: inspiration from metabolomics.Metabolomics : Official journal of the Metabolomic Society · 2024Review
- Rodent Models of Retinal Degeneration: From Purified Cells in Culture to Living Animals.Cold Spring Harbor perspectives in medicine · 2024Review
- Taurine: a promising nutraceutic in the prevention of retinal degeneration.Neural regeneration research · 2024Review
- Insights into the liver-eyes connections, from epidemiological, mechanical studies to clinical translation.Journal of translational medicine · 2023Review
- Vitamin A aldehyde-taurine adducts function in photoreceptor cells.Redox biology · 2022Article
- Therapeutic effect of the mesenchymal stem cells on vigabatrin-induced retinopathy in adult male albino rat.Anatomy & cell biology · 2022Article
- Taurine and Its Anticancer Functions: In Vivo and In Vitro Study.Advances in experimental medicine and biology · 2022Review
- Cytoprotective effect of taurine against sodium chlorate-induced oxidative damage in human red blood cells: an ex vivo study.Amino acids · 2022Article
- Glial Cell Activation and Oxidative Stress in Retinal Degeneration Induced by β-Alanine Caused Taurine Depletion and Light Exposure.International journal of molecular sciences · 2021Article
- New solutions for old challenges in glaucoma treatment: is taurine an option to consider?Neural regeneration research · 2021Article
- Taurine and oxidative stress in retinal health and disease.CNS neuroscience & therapeutics · 2021Review
- Preferential accumulation of the active S-(+) isomer in murine retina highlights novel mechanisms of vigabatrin-associated retinal toxicity.Epilepsy research · 2021Article
- Taurine Attenuates the Hypotaurine-Induced Progression of CRCFrontiers in cell and developmental biology · 2021Article
- Taurine treatment of retinal degeneration and cardiomyopathy in a consanguineous family with SLC6A6 taurine transporter deficiency.Human molecular genetics · 2020Article
- Vigabatrin-Induced Retinal Functional Alterations and Second-Order Neuron Plasticity in C57BL/6J Mice.Investigative ophthalmology & visual science · 2020Article
- Human Plasma Metabolomics in Age-Related Macular Degeneration: Meta-Analysis of Two Cohorts.Metabolites · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 1970s, taurine deficiency was reported to induce photoreceptor degeneration in cats and rats. Recently, we found that taurine deficiency contributes to the retinal toxicity of vigabatrin, an antiepileptic drug. However, in this toxicity, retinal ganglion cells were degenerating in parallel to cone photoreceptors. The aim of this study was to re-assess a classic mouse model of taurine deficiency following a treatment with guanidoethane sulfonate (GES), a taurine transporter inhibitor to determine whether retinal ganglion cells are also affected. GES treatment induced a significant reduction in the taurine plasma levels and a lower weight increase. At the functional level, photopic electroretinograms were reduced indicating a dysfunction in the cone pathway. A change in the autofluorescence appearance of the eye fundus was explained on histological sections by an increased autofluorescence of the retinal pigment epithelium. Although the general morphology of the retina was not affected, cell damages were indicated by the general increase in glial fibrillary acidic protein expression. When cell quantification was achieved on retinal sections, the number of outer/inner segments of cone photoreceptors was reduced (20 %) as the number of retinal ganglion cells (19 %). An abnormal synaptic plasticity of rod bipolar cell dendrites was also observed in GES-treated mice. These results indicate that taurine deficiency can not only lead to photoreceptor degeneration but also to retinal ganglion cell loss. Cone photoreceptors and retinal ganglion cells appear as the most sensitive cells to taurine deficiency. These results may explain the recent therapeutic interest of taurine in retinal degenerative pathologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.